Search

Your search keyword '"Aiba, Setsuya"' showing total 1,612 results
Start Over Author "Aiba, Setsuya"
1,612 results on '"Aiba, Setsuya"'

215. Association of Baseline Serum Levels of CXCL5 With the Efficacy of Nivolumab in Advanced Melanoma

Author

Fujimura, Taku, primary, Sato, Yota, additional, Tanita, Kayo, additional, Lyu, Chunbing, additional, Kambayashi, Yumi, additional, Amagai, Ryo, additional, Otsuka, Atsushi, additional, Fujisawa, Yasuhiro, additional, Yoshino, Koji, additional, Matsushita, Shigeto, additional, Uchi, Hiroshi, additional, Yamamoto, Yuki, additional, Hata, Hiroo, additional, Funakoshi, Takeru, additional, Nonomura, Yumi, additional, Tanaka, Ryota, additional, Okuhira, Hisako, additional, Wada, Naoko, additional, Hashimoto, Akira, additional, and Aiba, Setsuya, additional

Published
2019
Full Text
View/download PDF

217. FDG-PET detects extensive calcinosis cutis in anti-NXP2 antibody-positive dermatomyositis

Author

Nakamura, Naoko, primary, Izumi, Rumiko, additional, Hoshi, Yosuke, additional, Takai, Yoshiki, additional, Ono, Risako, additional, Suzuki, Naoki, additional, Nagai, Taichi, additional, Ishii, Yusho, additional, Ishii, Tomonori, additional, Harigae, Hideo, additional, Okada, Shuko, additional, Aiba, Setsuya, additional, Okiyama, Naoko, additional, Fujimoto, Manabu, additional, Kuroda, Hiroshi, additional, Tateyama, Maki, additional, and Aoki, Masashi, additional

Published
2019
Full Text
View/download PDF

223. Heat element of magnetic hyperthermia in mouse melanoma model

Author

Maruyama, Takeshi, Sawaya, Yukiko, Sato, Fumihiro, Matsuki, Hidetoshi, Aiba, Setsuya, Ito, Yumiko, and Sato, Tadakuni

Subjects
Melanoma -- Research, Ferrites (Magnetic materials) -- Usage, Ferrites (Magnetic materials) -- Health aspects, Tumors -- Research, Business, Electronics, Electronics and electrical industries
Abstract

The soft-heating method is one kind of heating technique of hyperthermia. The feature of this method is to use thermosensitive magnetic material as the heat element. This means the heat element can control the temperature automatically, referring the Curie-point of the thermosensitive ferrite. The heat element consists of a thermosensitive ferrite and metal ring. The purpose of the metal ring wrapped to ferrite is to increase heat quantity compared with that of ferrite alone. In this study, the effect of the heat element in mouse tumor model (B-16 melanoma) is examined. As a result, the tumors of mice were locally heated to the point at which tumor is necrotized in the condition of 200 kHz-6 mT. Index Terms--Hyperthermia, mouse melanoma, soft-heating method, thermosensitive ferrite.

Published
2006

226. Examination of the exciting condition for the high-temperature magnetic hyperthermia

Author

Sawaya, Yukiko, Suzuki, Nobutake, Sato, Fumihiro, Matsuki, Hidetoshi, Aiba, Setsuya, and Sato, Tadakuni

Subjects
Hyperthermia treatment systems (Medical care) -- Magnetic properties, Magnetic fields -- Research, Business, Electronics, Electronics and electrical industries
Abstract

The soft-heating method is one of the hyperthemia. The heater that consists of thermosensitive ferrite is implanted into the body, and heated by a high-frequency magnetic field. This paper applies the 'advanced' soft-heating method. A complex type of heater, composed of thermosensitive ferrite wound on a metallic ring, is created. This complex type of heater produces heat due to losses of hysteresis and inductive current. The effect of the exciting frequency on the heating value of a complex type of heater is examined. As a result, the area of 12 x 7 mm is heated over 60[degrees]C in phantom, in the condition of 6 mT-100 kHz. The heated area in vitro is confirmed, so a test in vivo is examined. The tumors of mice were heated to the point at which the tumor is necrotized. Index Terms--Exciting condition, hyperthermia, soft-heating method, thermosensitive ferrite.

Published
2005

232. Serum Level of Soluble CD163 May Be a Predictive Marker of the Effectiveness of Nivolumab in Patients With Advanced Cutaneous Melanoma

Author

Fujimura, Taku, Sato, Yota, Tanita, Kayo, Kambayashi, Yumi, Otsuka, Atsushi, Fujisawa, Yasuhiro, Yoshino, Koji, Matsushita, Shigeto, Funakoshi, Takeru, Hata, Hiroo, Yamamoto, Yuki, Uchi, Hiroshi, Nonomura, Yumi, Tanaka, Ryota, Aoki, Megumi, Imafuku, Keisuke, Okuhira, Hisako, Wada, Naoko, Irie, Hiroyuki, Hidaka, Takanori, Hashimoto, Akira, Aiba, Setsuya, Fujimura, Taku, Sato, Yota, Tanita, Kayo, Kambayashi, Yumi, Otsuka, Atsushi, Fujisawa, Yasuhiro, Yoshino, Koji, Matsushita, Shigeto, Funakoshi, Takeru, Hata, Hiroo, Yamamoto, Yuki, Uchi, Hiroshi, Nonomura, Yumi, Tanaka, Ryota, Aoki, Megumi, Imafuku, Keisuke, Okuhira, Hisako, Wada, Naoko, Irie, Hiroyuki, Hidaka, Takanori, Hashimoto, Akira, and Aiba, Setsuya

Abstract

Antibodies against programmed cell death protein 1, such as nivolumab and pembrolizumab, are widely used for treating various cancers, including advanced melanoma. Nivolumab significantly prolongs survival in patients with metastatic melanoma, and sequential administration with lipilimumab may improve outcomes when switched at the appropriate time. Biomarkers are therefore needed to evaluate nivolumab efficacy soon after first administration. This study analyzed serum levels of soluble cluster of differentiation 163 (sCD163) in 59 cases of advanced cutaneous melanoma and 16 cases of advanced mucosal melanoma treated using nivolumab. Serum levels of sCD163 were significantly increased after 6 weeks in responders compared to non-responders after initial administration of nivolumab for cutaneous melanoma. In contrast, no significant difference between responders and non-responders was seen among patients with non-cutaneous melanoma. These results suggest that sCD163 may be useful as a biomarker for selecting patients with advanced cutaneous melanoma most likely to benefit from anti-melanoma immunotherapy.

Published
2018

233. Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study

Author

Fujimura, Taku, Sato, Yota, Tanita, Kayo, Kambayashi, Yumi, Otsuka, Atsushi, Fujisawa, Yasuhiro, Yoshino, Koji, Matsushita, Shigeto, Funakoshi, Takeru, Hata, Hiroo, Yamamoto, Yuki, Uchi, Hiroshi, Nonomura, Yumi, Tanaka, Ryota, Aoki, Megumi, Imafuku, Keisuke, Okuhira, Hisako, Furudate, Sadanori, Hidaka, Takanori, Aiba, Setsuya, Fujimura, Taku, Sato, Yota, Tanita, Kayo, Kambayashi, Yumi, Otsuka, Atsushi, Fujisawa, Yasuhiro, Yoshino, Koji, Matsushita, Shigeto, Funakoshi, Takeru, Hata, Hiroo, Yamamoto, Yuki, Uchi, Hiroshi, Nonomura, Yumi, Tanaka, Ryota, Aoki, Megumi, Imafuku, Keisuke, Okuhira, Hisako, Furudate, Sadanori, Hidaka, Takanori, and Aiba, Setsuya

Abstract

Antibodies against PD-1, such as nivolumab and pembrolizumab, are widely used in the treatment of various cancers including advanced melanoma. The anti-PD-1 Ab significantly prolongs survival in patients with metastatic melanoma, and its administration in combination with local or systemic therapy may also lead to improved outcomes. Although anti-PD-1 Ab-based combined therapy might be effective for the treatment of advanced melanoma, the associated risk of irAEs is an important consideration. Therefore, being able to predict irAEs is of great interest to oncologists. The purpose of this study was to evaluate the value of using serum levels of sCD163 and CXCL5 to predict irAEs in patients with advanced melanoma who were administered nivolumab. To this end, we analyzed these serum levels in 46 cases of advanced melanoma treated with nivolumab. In addition, the tumor stroma was evaluated by immunohistochemistry and immunofluorescence. We measured the serum levels of sCD163 and CXCL5 on day 0 (immediately before nivolumab administration) and day 42. The serum absolute levels of sCD163 were significantly increased in patients who developed AEs (p = 0.0018). Although there was no significant difference in serum levels of CXCL5, the absolute value of CXCL5 could at least be a supportive marker for the increased absolute levels of serum sCD163. This study suggests that sCD163 and CXCL5 may serve as possible prognostic biomarkers for irAEs in patients with advanced melanoma treated with nivolumab.

Published
2018

237. Possible roles of CXCL13/CXCR5 axis in the development of bullous pemphigoid.

Author

Ohuchi, Kentaro, Fujimura, Taku, Lyu, Chunbing, Amagai, Ryo, Muto, Yusuke, and Aiba, Setsuya

Abstract

CXCL13 recruits CXCR5+ follicular helper T (Tfh) cells in inflammatory lesions to develop secondary lymphoid organs. Tfh cells activate B cells to produce antibodies during humoral immune responses. Indeed, as previous reports suggested, CXCR5+ cell numbers were increased in the peripheral blood of bullous pemphigoid (BP) patients when compared with healthy donors, and the ratio of CXCR5+ cells was positively correlated with the anti‐BP180‐NC16A titers. From the above findings, in this report, we hypothesized that a chemokine related to CXCR5+ cells, namely CXCL13, may play a role in the development of BP. We performed immunohistochemical staining of CXCR5, CXCL13, LL37, CXCL10 and CCL20 for 10 cases of BP and 10 cases of pemphigus vulgaris (PV), and quantitatively analyzed the staining by digital microscopy. Moreover, we investigated the CXCL10 and CXCL13 production in BP and PV patients by enzyme‐linked immunosorbent assay. The immunomodulatory effects of LL37 on the production of T‐helper 17‐related chemokines were evaluated using monocyte‐derived M2 macrophages. Immunohistochemical staining and digital microscopic analysis showed that the ratios of CXCR5+, CXCL13+ and LL37+ cells in the dermis were significantly higher in BP patients than in PV patients. Notably, the ratio of CXCL13+ cells was positively correlated with the anti‐BP180‐NC16A titers. Moreover, the serum levels of CXCL13 were positively correlated with the anti‐BP180‐NC16A titers. Furthermore, CD163+ M2 macrophages stimulated by LL37 in vitro produced CXCL10 and CCL20. In the lesional skin of BP, CD163+ macrophages CXCL10 and CCL20 were produced. The serum levels of CXCL10 were negatively correlated with the anti‐BP180‐NC16A titers. The present study results indicate that the mechanism of the development of BP may involve the CXCL13/CXCR5‐mediated migration of Tfh cells. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

238. Case series of BRAF‐mutated advanced melanoma treated with encorafenib plus binimetinib combination therapy.

Author

Fujimura, Taku, Yoshino, Koji, Kato, Hiroshi, Fujisawa, Yasuhiro, Nakamura, Yoshiyuki, Yamamoto, Yuki, Kunimoto, Kayo, Ito, Takamichi, Matsushita, Shigeto, Maekawa, Takeo, Ohuchi, Kentaro, Amagai, Ryo, Muto, Yusuke, Furudate, Sadanori, Kambayashi, Yumi, Hashimoto, Akira, and Aiba, Setsuya

Abstract

The efficacy of encorafenib plus binimetinib (E + B) combination therapy for BRAF‐mutated advanced melanoma as second‐line therapy and beyond is still unknown. In this report, we investigated 22 cases of BRAF‐mutated advanced melanoma treated with E + B combination therapy. The objective response rate (ORR) for the total cohort was 68.4%. Notably, the ORR for the second‐line and beyond cohort was 73.3%, suggesting that the therapeutic effect of E + B combination therapy is comparable with that of first‐line targeted therapy. In contrast, overall survival and progress‐free survival in our present cohort was worse than that in a previous clinical trial. Notably, although the incidence rate of severe adverse events was higher than that in a previous report, our present study suggested that E + B combination therapy is a well‐tolerated antimelanoma regimen. Our present study suggested that the efficacy and safety profile of E + B combination therapy as a second‐line therapy and beyond is comparable with that of first‐line targeted therapy. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

239. Serum soluble CD163 and proinflammatory chemokines may be biomarkers of the onset of adverse events in dabrafenib plus trametinib combination therapy for advanced melanoma.

Author

Amagai, Ryo, Fujimura, Taku, Muto, Yusuke, Kambayashi, Yumi, Furudate, Sadanori, Ohuchi, Kentaro, Okuma, Takami, Hashimoto, Akira, and Aiba, Setsuya

Subjects
CHEMOKINES, JUVENILE idiopathic arthritis, SERUM, T cells, BIOMARKERS, MELANOMA
Abstract

Various adverse events (AEs) have been reported to occur at a high rate in patients treated with dabrafenib plus trametinib (D + T) combination therapy. Among such AEs, the incidence of pyrexia was highest among the series of AEs in patients treated with D + T combination therapy. Although little is known about the mechanisms of pyrexia caused by D + T combination therapy, a recent report suggested that sCD163, as well as interferon‐inducible chemokines (CXCL9, CXCL10, CXCL11), might correlate with pyrexia caused by encorafenib plus binimetinib combination therapy. In addition to these soluble factors, CXCL5 is a biomarker for predicting immune‐related AEs in melanoma patients treated with nivolumab. From the above findings, we hypothesized that these soluble factors might also correlate with the onset of AEs in D + T combination therapy. The serum levels of sCD163 were increased in patients with pyrexia in parallel with their severity, whereas the serum levels of CXCL5 were increased in patients without pyrexia. Moreover, increased levels of CXCL9, CXCL10, and CXCL11 were prominent in patients with AEs over G2 levels. As these chemokines recruit Th1, Th17, and activated CD8+ T cells, increased serum levels of these chemokines might correlate with the positive feedback of inflammatory reactions related to AEs. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

244. Serum Level of Soluble CD163 May Be a Predictive Marker of the Effectiveness of Nivolumab in Patients With Advanced Cutaneous Melanoma

Author

Fujimura, Taku, primary, Sato, Yota, additional, Tanita, Kayo, additional, Kambayashi, Yumi, additional, Otsuka, Atsushi, additional, Fujisawa, Yasuhiro, additional, Yoshino, Koji, additional, Matsushita, Shigeto, additional, Funakoshi, Takeru, additional, Hata, Hiroo, additional, Yamamoto, Yuki, additional, Uchi, Hiroshi, additional, Nonomura, Yumi, additional, Tanaka, Ryota, additional, Aoki, Megumi, additional, Imafuku, Keisuke, additional, Okuhira, Hisako, additional, Wada, Naoko, additional, Irie, Hiroyuki, additional, Hidaka, Takanori, additional, Hashimoto, Akira, additional, and Aiba, Setsuya, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results